An update on the use and investigation of probiotics in health and disease

Gut

Volumn 62, Issue 5, 2013, Pages 787-796

  Sanders, Mary Ellen ^a   Guarner, Francisco ^b   Guerrant, Richard ^c   Holt, Peter R ^d   Quigley, Eamonn M M ^e,f   Sartor, R Balfour ^g   Sherman, Philip M ^h   Mayer, Emeran A ⁱ  

^a DAIRY AND FOOD CULTURE TECHNOLOGIES   (United States)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c UNIVERSITY OF VIRGINIA   (United States)

^d ROCKEFELLER UNIVERSITY   (United States)

^e UNIVERSITY COLLEGE CORK   (Ireland)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^h HOSPITAL FOR SICK CHILDREN   (Canada)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PROBIOTIC AGENT;

ALLERGIC DISEASE; ARTICLE; BACTERIAL STRAIN; BIFIDOBACTERIUM BIFIDUM; CANCER PREVENTION; CANCER THERAPY; COLORECTAL CANCER; CROHN DISEASE; DRUG CONTROL; DRUG EFFICACY; DRUG INDICATION; DRUG MARKETING; DRUG USE; ENTERITIS; FLU LIKE SYNDROME; HEALTH STATUS; HUMAN; IMMUNOMODULATION; INFECTIOUS DIARRHEA; INTESTINE INJURY; IRRITABLE COLON; LACTOBACILLUS RHAMNOSUS; NECROTIZING ENTEROCOLITIS; NONHUMAN; PRIORITY JOURNAL; RISK REDUCTION; STREPTOCOCCUS THERMOPHILUS; STUDY DESIGN; TREATMENT OUTCOME; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION;

COLITIS, ULCERATIVE; COLORECTAL NEOPLASMS; CROHN DISEASE; CROSS INFECTION; DIARRHEA; ENTEROCOLITIS, NECROTIZING; EVIDENCE-BASED MEDICINE; FEMALE; HEALTH STATUS; HUMANS; HYPERSENSITIVITY; IRRITABLE BOWEL SYNDROME; META-ANALYSIS AS TOPIC; PROBIOTICS; VAGINITIS;

EID: 84875863443     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2012-302504     Document Type: Article

References (119)

1. Neish AS. Microbes in gastrointestinal health and disease. Gastroenterology [Research Support, N.I.H., Extramural Review] 2009;136:65-80.
2. Bron PA, van Baarlen P, Kleerebezem M. Emerging molecular insights into the interaction between probiotics and the host intestinal mucosa. Nat Rev Microbiol 2012;10:66-78.
3. McNulty NP, Yatsunenko T, Hsiao A, et al. The impact of a consortium of fermented milk strains on the gut microbiome of gnotobiotic mice and monozygotic twins. Sci Transl Med [Research Support, N.I.H., Extramural] 2011;3:106ra.
4. Ringel Y, Quigley E, Lin H. Probiotics and gastrointestinal disorders. Am J Gastroenterol Suppl 2012;1:34-40.
5. Spiller R, Aziz Q, Creed F, et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 2007;56:1770-98. (Pubitemid 350206308)
6. Quigley EM, Locke GR, Mueller-Lissner S, et al. Prevalence and management of abdominal cramping and pain: a multinational survey. Aliment Pharmacol Ther 2006;24:411-19. (Pubitemid 43972910)
7. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006;30:1480-91.
8. Moayyedi P, Ford AC. Symptom-based diagnostic criteria for irritable bowel syndrome: the more things change, the more they stay the same. Gastroenterol Clin North Am 2011;40:87-103.
9. European Food Safety Authority. Guidance on the scientific requirements for health claims related to gut and immune function. EFSA Journal 2011;9:1-12.
10. Kassinen A, Krogius-Kurikka L, Makivuokko H, et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 2007;133:24-33. (Pubitemid 47031125)
11. Saulnier DM, Riehle K, Mistretta TA, et al. Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome. Gastroenterology 2011;141:1782-91.
12. Rajilic-Stojanovic M, Biagi E, Heilig HG, et al. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology [Research Support, Non-U.S. Gov't] 2011;141:1792-801.
13. Jeffery IB, O'Toole PW, Ohman L, et al. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut [Research Support, Non-U.S. Gov't] 2012;61:997-1006.
14. Jeffery IB, Quigley EM, Ohman L, et al. The microbiota link to irritable bowel syndrome: an emerging story. Gut Microbes 2012;3:572-6.
15. Carroll IM, Ringel-Kulka T, Keku TO, et al. Molecular analysis of the luminal-and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol [Research Support, N.I.H., Extramural] 2011;301:G799-807.
16. Rhee SH, Pothoulakis C, Mayer EA. Principles and clinical implications of the brain-gut-enteric microbiota axis. Nat Rev Gastroenterol Hepatol [Research Support, N.I.H., Extramural Review] 2009;6:306-14.
17. Kunze WA, Mao YK, Wang B, et al. Lactobacillus reuteri enhances excitability of colonic AH neurons by inhibiting calcium-dependent potassium channel opening. J Cell Mol Med 2009;13:2261-70.
18. Tillisch K, Labus J, Ebrat B, et al. Modulation of the brain-gut axis after 4-week intervention with a probiotic fermented dairy product. Gastroenterology 2012;142(5 Suppl 1):S-115.
19. Moayyedi P, Ford AC, Talley NJ, et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 2010;59:325-32.
20. Clarke G, Cryan JF, Dinan TG, et al. Review article: probiotics for the treatment of irritable bowel syndrome-focus on lactic acid bacteria. Aliment Pharmacol Ther [Research Support, Non-U.S. Gov't Review] 2012;35:403-13.
21. Brenner DM, Moeller MJ, Chey WD, et al. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol [Review] 2009;104:1033-49; quiz 50.
22. O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology [Clinical Trial Randomized Controlled Trial Research Support, Non-U.S. Gov't] 2005;128:541-51. (Pubitemid 40585355)
23. Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol [Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't] 2006;101:1581-90. (Pubitemid 43980633)
24. Black RE, Cousens S, Johnson HL, et al. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet [Comparative Study Research Support, Non-U.S. Gov't] 2010;375:1969-87.
25. Preidis GA, Hill C, Guerrant RL, et al. Probiotics, enteric and diarrheal diseases, and global health. Gastroenterology 2011;140:8-14.
26. Guerrant RL, Kosek M, Lima AA, et al. Updating the DALYs for diarrhoeal disease. Trends Parasitol [News Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.] 2002;18:191-3. (Pubitemid 34442585)
27. Guerrant RL, Oria RB, Moore SR, et al. Malnutrition as an enteric infectious disease with long-term effects on child development. Nutr Rev [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review]. 2008;66:487-505.
28. Allen SJ, Martinez EG, Gregorio GV, et al. Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev 2010(11):CD003048.
29. Bernaola Aponte G, Bada Mancilla CA, Carreazo Pariasca NY, et al. Probiotics for treating persistent diarrhoea in children. Cochrane Database Syst Rev 2010(11): CD007401.
30. Preidis GA, Versalovic J. Targeting the human microbiome with antibiotics, probiotics, and prebiotics: gastroenterology enters the metagenomics era. Gastroenterology 2009;136:2015-31.
31. Guandalini S. Probiotics for prevention and treatment of diarrhea. J Clin Gastroenterol [Review]. 2011;45(Suppl):S149-53.
32. Floch MH, Walker WA, Madsen K, et al. Recommendations for probiotic use-2011 update. J Clin Gastroenterol [Consensus Development Conference Practice Guideline Research Support, Non-U.S. Gov't] 2011;45(Suppl):S168-71.
33. Szajewska H, Ruszczynski M, Radzikowski A. Probiotics in the prevention of antibiotic-associated diarrhea in children: a meta-analysis of randomized controlled trials. J Pediatr 2006;149:367-72.
34. Parkes GC, Sanderson JD, Whelan K. The mechanisms and efficacy of probiotics in the prevention of Clostridium difficile-associated diarrhoea. Lancet Infect Dis 2009;9:237-44.
35. Hickson M, D'Souza AL, Muthu N, et al. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ 2007;335:80.
36. Gao XW, Mubasher M, Fang CY, et al. Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. Am J Gastroenterol 2010;105:1636-41.
37. Scott RD II. The direct medical costs of healthcare-associated infections in U.S. hospitals and the benefits of prevention. Centers for Disease Control and Prevention. 2009;http://www.cdc.gov/HAI/pdfs/hai/Scott-CostPaper.pdf (accessed 25 Feb 2013).
38. Morrow LE, Kollef MH, Casale TB. Probiotic prophylaxis of ventilator-associated pneumonia: a blinded, randomized, controlled trial. Am J Respir Crit Care Med [Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't] 2010;182:1058-64.
39. Hojsak I, Abdovic S, Szajewska H, et al. Lactobacillus GG in the prevention of nosocomial gastrointestinal and respiratory tract infections. Pediatrics 2010;125: -1171-7.
40. Mihatsch WA, Vossbeck S, Eikmanns B, et al. Effect of Bifidobacterium lactis on the incidence of nosocomial infections in very-low-birth-weight infants: a randomized controlled trial. Neonatology [Randomized Controlled Trial Research Support, Non-U.S. Gov't] 2010;98:156-63.
41. Honeycutt TC, El Khashab M, Wardrop RM III, et al. Probiotic administration and the incidence of nosocomial infection in pediatric intensive care: a randomized placebo-controlled trial. Pediatr Crit Care Med [Randomized Controlled Trial Research Support, Non-U.S. Gov't] 2007;8:452-8; quiz 64. (Pubitemid 47415298)
42. Szajewska H, Kotowska M, Mrukowicz JZ, et al. Efficacy of Lactobacillus GG in prevention of nosocomial diarrhea in infants. J Pediatr [Clinical Trial Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't] 2001;138:361-5. (Pubitemid 32207138)
43. Mastretta E, Longo P, Laccisaglia A, et al. Effect of Lactobacillus GG and breast-feeding in the prevention of rotavirus nosocomial infection. J Pediatr Gastroenterol Nutr [Clinical Trial Randomized Controlled Trial] 2002;35:527-31. (Pubitemid 35191072)
44. Szajewska H, Wanke M, Patro B. Meta-analysis: the effects of Lactobacillus rhamnosus GG supplementation for the prevention of healthcare-associated diarrhoea in children. Aliment Pharmacol Ther [Research Support, Non-U.S. Gov't] 2011;34:1079-87.
45. Saavedra JM, Bauman NA, Oung I, et al. Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus. Lancet [Clinical Trial Randomized Controlled Trial Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.] 1994;344:1046-9. (Pubitemid 24310035)
46. Barraud D, Blard C, Hein F, et al. Probiotics in the critically ill patient: a double blind, randomized, placebo-controlled trial. Intensive Care Med [Randomized Controlled Trial Research Support, Non-U.S. Gov't] 2010;36:1540-7.
47. Besselink MG, van Santvoort HC, Buskens E, et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet [Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't] 2008;371:651-9.
48. Shanahan F, Collins SM. Pharmabiotic manipulation of the microbiota in gastrointestinal disorders, from rationale to reality. Gastroenterol Clin North Am 2010;39:721-6.
49. Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology 2008;134:577-94. (Pubitemid 351173057)
50. Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut [Clinical Trial Multicenter Study Randomized Controlled Trial] 2004;53:1617-23. (Pubitemid 39434105)
51. Miele E, Pascarella F, Giannetti E, et al. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol [Randomized Controlled Trial] 2009;104:437-43.
52. Sood A, Midha V, Makharia GK, et al. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol [Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't] 2009;7:1202-9, 9 -1.
53. Tursi A, Brandimarte G, Papa A, et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol [Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't] 2010;105:2218-27.
54. McGovern DP, Jones MR, Taylor KD, et al. Fucosyltransferase 2 (FUT2) non-secretor status is associated with Crohn's disease. Hum Mol Genet 2010;19:3468-76.
55. Yan F, Polk D. Lactobacillus rhamnosus GG-an updated strategy to use microbial products to promote health. Functional Food Rev 2012;4:41-8.
56. Round JL, Lee SM, Li J, et al. The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. Science 2011;332: 974-7.
57. Mohamadzadeh M, Pfeiler EA, Brown JB, et al. Regulation of induced colonic inflammation by Lactobacillus acidophilus deficient in lipoteichoic acid. Proc Natl Acad Sci USA 2011;108(Suppl 1):4623-30.
58. Whitehead KJ, Schmitz JM, Carroll I, et al. Ingestion of dietary carbohydrates influences the aggressiveness of colitis and intestinal microbial composition in IL-10-/-mice. Gastroenterology 2011;138:A51.
59. Matsuura M, Liu B, Carroll I, et al. Selective alteration of growth and virulence for iron-dependent bacterial species; Possible novel mechanisms of detrimental effects of dietary iron on intestinal inflammation. Gastroenterology 2011;138:A734.
60. Neu J, Walker WA. Necrotizing enterocolitis. N Engl J Med [Review] 2011;364:255-64.
61. Morowitz MJ, Poroyko V, Caplan M, et al. Redefining the role of intestinal microbes in the pathogenesis of necrotizing enterocolitis. Pediatrics [Review] 2010;125:777-85.
62. Wang Y, Hoenig JD, Malin KJ, et al. 16S rRNA gene-based analysis of fecal microbiota from preterm infants with and without necrotizing enterocolitis. ISME J [Research Support, N.I.H., Extramural] 2009;3:944-54.
63. Mai V, Young CM, Ukhanova M, et al. Fecal microbiota in premature infants prior to necrotizing enterocolitis. PLoS One 2011;6:-20647.
64. Nanthakumar NN, Fusunyan RD, Sanderson I, et al. Inflammation in the developing human intestine: A possible pathophysiologic contribution to necrotizing enterocolitis. Proc Natl Acad Sci USA 2000;97:6043-8. (Pubitemid 30367520)
65. Deshpande G, Rao S, Patole S, et al. Updated meta-analysis of probiotics for preventing necrotizing enterocolitis in preterm neonates. Pediatrics [Meta-Analysis] 2010;125:921-30.
66. Awad H, Mokhtar H, Imam SS, et al. Comparison between killed and living probiotic usage versus placebo for the prevention of necrotizing enterocolitis and sepsis in neonates. Pak J Biol Sci 2010;13:253-62.
67. Thomas DW, Greer FR. Probiotics and prebiotics in pediatrics. Pediatrics [Review] 2010;126:1217-31.
68. Szajewska H, Guandalini S, Morelli L, et al. Effect of Bifidobacterium animalis subsp lactis supplementation in preterm infants: a systematic review of randomized controlled trials. J Pediatr Gastroenterol Nutr [Meta-Analysis Research Support, Non-U.S. Gov't Review] 2010;51:203-9.
69. Alfaleh K, Anabrees J, Bassler D, et al. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev [Meta-Analysis Review] 2011(3):CD005496.
70. Vannucci L, Stepankova R, Kozakova H, et al. Colorectal carcinogenesis in germ-free and conventionally reared rats: different intestinal environments affect the systemic immunity. Int J Oncol 2008;32:609-17. (Pubitemid 351330467)
71. Sears CL, Pardoll DM. Perspective: alpha-bugs, their microbial partners, and the link to colon cancer. J Infect Dis [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't] 2011;203:306-11.
72. Chen W, Liu F, Ling Z, et al. Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer. PLoS One 2012;7:-39743.
73. Sobhani I, Tap J, Roudot-Thoraval F, et al. Microbial dysbiosis in colorectal cancer (CRC) patients. PLoS One 2011;6:-16393.
74. Marchesi JR, Dutilh BE, Hall N, et al. Towards the human colorectal cancer microbiome. PLoS One [Research Support, Non-U.S. Gov't] 2011;6:-20447.
75. Castellarin M, Warren RL, Freeman JD, et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res [Research Support, Non-U.S. Gov't] 2012;22:299-306.
76. Saikali J, Picard C, Freitas M, et al. Fermented milks, probiotic cultures, and colon cancer. Nutr Cancer 2004;49:14-24. (Pubitemid 39299122)
77. Zhu Y, Michelle Luo T, Jobin C, et al. Gut microbiota and probiotics in colon tumorigenesis. Cancer Lett 2011;309:119-27.
78. Azcarate-Peril MA, Sikes M, Bruno-Barcena JM. The intestinal microbiota, gastrointestinal environment and colorectal cancer: a putative role for probiotics in prevention of colorectal cancer? Am J Physiol Gastrointest Liver Physiol [Review] 2011;301:G401-24.
79. Rowland IR. The role of the gastrointestinal microbiota in colorectal cancer. Curr Pharm Des 2009;15:1524-7.
80. Pearson JR, Gill CI, Rowland IR. Diet, fecal water, and colon cancer-development of a biomarker. Nutr Rev 2009;67:509-26.
81. Worthley DL, Le Leu RK, Whitehall VL, et al. A human, double-blind, placebo-controlled, crossover trial of prebiotic, probiotic, and synbiotic supplementation: effects on luminal, inflammatory, epigenetic, and epithelial biomarkers of colorectal cancer. Am J Clin Nutr 2009;90:578-86.
82. Rafter J, Bennett M, Caderni G, et al. Dietary synbiotics reduce cancer risk factors in polypectomized and colon cancer patients. Am J Clin Nutr [Randomized Controlled Trial Research Support, Non-U.S. Gov't] 2007;85:488-96. (Pubitemid 46220953)
83. Ishikawa H, Akedo I, Otani T, et al. Randomized trial of dietary fiber and Lactobacillus casei administration for prevention of colorectal tumors. Int J Cancer 2005;116:762-7. (Pubitemid 41099707)
84. Pala V, Sieri S, Berrino F, et al. Yogurt consumption and risk of colorectal cancer in the Italian European prospective investigation into cancer and nutrition cohort. Int J Cancer 2011;129:2712-9.
85. Crawford PA, Gordon JI. Microbial regulation of intestinal radiosensitivity. Proc Natl Acad Sci USA 2005;102:13254-9. (Pubitemid 41325010)
86. Xue H, Field CJ, Sawyer MB, et al. Prophylactic ciprofloxacin treatment prevented high mortality, and modified systemic and intestinal immune function in tumour-bearing rats receiving dose-intensive CPT-11 chemotherapy. Br J Cancer 2009;100:1581-8.
87. Ciorba MA, Stenson WF. Probiotic therapy in radiation-induced intestinal injury and repair. Ann N Y Acad Sci 2009;1165:190-4.
88. Osterlund P, Ruotsalainen T, Korpela R, et al. Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. Br J Cancer 2007;97:1028-34. (Pubitemid 47587008)
89. Chitapanarux I, Chitapanarux T, Traisathit P, et al. Randomized controlled trial of live lactobacillus acidophilus plus bifidobacterium bifidum in prophylaxis of diarrhea during radiotherapy in cervical cancer patients. Radiat Oncol 2010;5:31.
90. Delia P, Sansotta G, Donato V, et al. Use of probiotics for prevention of radiation-induced diarrhea. Tumori 2007;93:(Suppl) 1-6. (Pubitemid 46866726)
91. Movsas B, Vikram B, Hauer-Jensen M, et al. Decreasing the adverse effects of cancer therapy: National Cancer Institute guidance for the clinical development of radiation injury mitigators. Clin Cancer Res 2011;17:222-8.
92. Bjorksten B, Sepp E, Julge K, et al. Allergy development and the intestinal microflora during the first year of life. J Allergy Clin Immunol [Research Support, Non-U.S. Gov't] 2001;108:516-20. (Pubitemid 32978019)
93. Dominguez-Bello MG, Costello EK, Contreras M, et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci USA [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't] 2010;107:11971-5.
94. Shane AL, Cabana MD, Vidry S, et al. Guide to designing, conducting, publishing and communicating results of clinical studies involving probiotic applications in human participants. Gut Microbes 2010;1:243-53.
95. Folster-Holst R. Probiotics in the treatment and prevention of atopic dermatitis. Ann Nutr Metab 2010;57:16-19.
96. Skoner DP. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol 2001;108(1 Suppl):S2-8.
97. Mannheimer SB, Mukherjee R, Hirschhorn LR, et al. The CASE adherence index: a novel method for measuring adherence to antiretroviral therapy. AIDS Care 2006;18:853-61. (Pubitemid 44395534)
98. Stecher B, Hardt WD. Mechanisms controlling pathogen colonization of the gut. Curr Opin Microbiol [Research Support, Non-U.S. Gov't Review] 2011;14:82-91.
99. Borchers AT, Selmi C, Meyers FJ, et al. Probiotics and immunity. J Gastroenterol [Review] 2009;44:26-46.
100. Hao Q, Lu Z, Dong BR, et al. Probiotics for preventing acute upper respiratory tract infections. Cochrane Database Syst Rev [Meta-Analysis Review] 2011(9): CD006895.
101. Merenstein D, Murphy M, Fokar A, et al. Use of a fermented dairy probiotic drink containing Lactobacillus casei (DN-114 001) to decrease the rate of illness in kids: the DRINK study. A patient-oriented, double-blind, cluster-randomized, placebo-controlled, clinical trial. Eur J Clin Nutr [Randomized Controlled Trial Research Support, Non-U.S. Gov't] 2010;64:669-77.
102. Sazawal S, Dhingra U, Hiremath G, et al. Prebiotic and probiotic fortified milk in prevention of morbidities among children: community-based, randomized, double-blind, controlled trial. PLoS One [Randomized Controlled Trial Research Support, Non-U.S. Gov't] 2010;5:-12164.
103. Leyer GJ, Li S, Mubasher ME, et al. Probiotic effects on cold and influenza-like symptom incidence and duration in children. Pediatrics [Comparative Study Randomized Controlled Trial Research Support, Non-U.S. Gov't] 2009;124:-172-9.
104. Sur D, Manna B, Niyogi SK, et al. Role of probiotic in preventing acute diarrhoea in children: a community-based, randomized, double-blind placebo-controlled field trial in an urban slum. Epidemiol Infect [Randomized Controlled Trial Research Support, Non-U.S. Gov't] 2011;139:919-26.
105. de Vrese M, Winkler P, Rautenberg P, et al. Probiotic bacteria reduced duration and severity but not the incidence of common cold episodes in a double blind, randomized, controlled trial. Vaccine [Randomized Controlled Trial] 2006;24:6670-4. (Pubitemid 46107165)
106. Guarner F, Sanders ME, Gibson G, et al. Probiotic and prebiotic claims in Europe: seeking a clear roadmap. Br J Nutr 2011Jun 21:1-3.
107. Klein M, Sanders ME, Duong T, et al. Probiotics: from bench to market. Ann N Y Acad Sci 2010;1212(Suppl 1):-1-14.
108. Sanders ME, Levy DD. The science and regulations of probiotic food and supplement product labeling. Ann N Y Acad Sci 2011;1219(Suppl 1):-1-23.
109. Degnan FH. Clinical studies involving probiotics: when FDA's investigational new drug rubric applies-and when it may not. Gut Microbes 2012;3.
110. Gareau MG, Sherman PM, Walker WA. Probiotics and the gut microbiota in intestinal health and disease. Nat Rev Gastroenterol Hepatol 2010;7:503-14.
111. Bäckhed F, Fraser C, Ringel Y, et al. Defining a healthy human gut microbiome: current concepts, future directions, and clinical applications. Cell Host Microbe 2012;12:611-22.
112. Focareta A, Paton JC, Morona R, et al. A recombinant probiotic for treatment and prevention of cholera. Gastroenterology 2006;130:1688-95. (Pubitemid 43668856)
113. Takiishi T, Korf H, Van Belle TL, et al. Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice. J Clin Invest [Research Support, Non-U.S. Gov't] 2012;122:1717-25.
114. Lebeer S, Vanderleyden J, De Keersmaecker SC. Host interactions of probiotic bacterial surface molecules: comparison with commensals and pathogens. Nat Rev Microbiol 2010;8:171-84.
115. Aroniadis OC, Brandt LJ. Fecal microbiota transplantation: past, present and future. Curr Opin Gastroenterol 2013;29:79-84.
116. Vrieze A, Van Nood E, Holleman F, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012;143:913-16 -7.
117. Wells JM, Mercenier A. Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat Rev Microbiol [Research Support, Non-U. S. Gov't Review] 2008;6:349-62. (Pubitemid 351552656)
118. Atarashi K, Tanoue T, Shima T, et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science 2011;331:337-41.
119. Sartor RB. Genetics and environmental interactions shape the intestinal microbiome to promote inflammatory bowel disease versus mucosal homeostasis. Gastroenterology 2010;139:1816-19.